Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Rituximab 41Cyclophosphamide 23Peripheral Blood Stem Cell Transplantation 15Lenalidomide 14ibrutinib 11fludarabine phosphate 11Etoposide 10Bortezomib 10Filgrastim 9Bendamustine Hydrochloride 9Mycophenolic Acid 8Melphalan 8Cytarabine 8venetoclax 7fludarabine 7Whole-Body Irradiation 7Vincristine 7Cyclosporine 7CT-P10 7Methotrexate 6obinutuzumab 5acalabrutinib 5Doxorubicin 5Carmustine 5Carboplatin 5Biopsy 5pembrolizumab 4ibritumomab tiuxetan 4carmustine, poliferprosan 20 drug combination 4Tacrolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Mantle-Cell × MLN 8237 × Clear all
NCT01397825 2018-03-27

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Takeda

Phase 1/2 Completed
45 enrolled 24 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡